AXSOME THERAPEUTICS, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
AXSOME THERAPEUTICS, INC. (AXSM) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $63.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $46.61M, a 116.75% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $17.23M, a 2006.23% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $7.17M, a 72.05% decline year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $54.25M, a 919.11% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $83.74M, a 49.37% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $56.06M, a 53.81% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $36.45M, a 17.01% decline from fiscal 2022.
- AXSOME THERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $43.92M, a 7446.91% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $46.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $63.84M 10-Q · filed 2026-08-10 | $71.01M derived: sum of 3 quarters · filed 2026-08-10 | $125.26M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $17.23M 10-Q · filed 2026-05-04 | $24.40M derived: sum of 2 quarters · filed 2026-05-04 | $78.65M derived: sum of 3 quarters · filed 2026-05-04 | $100.15M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $61.42M derived: sum of 2 quarters · filed 2026-02-23 | $82.92M derived: sum of 3 quarters · filed 2026-08-10 | $83.74M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $54.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $75.75M derived: sum of 2 quarters · filed 2026-08-10 | $76.57M 10-Q · filed 2025-11-03 | $102.24M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $22.32M 10-Q · filed 2026-08-10 | $47.99M derived: sum of 3 quarters · filed 2026-08-10 | $53.31M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $818.00K 10-Q · filed 2026-05-04 | $26.49M derived: sum of 2 quarters · filed 2026-05-04 | $31.81M derived: sum of 3 quarters · filed 2026-05-04 | $65.30M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $25.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $30.99M derived: sum of 2 quarters · filed 2026-02-23 | $64.48M derived: sum of 3 quarters · filed 2026-02-23 | $56.06M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $38.81M derived: sum of 2 quarters · filed 2025-11-03 | $30.39M 10-Q · filed 2025-11-03 | $41.76M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $33.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $25.07M 10-Q · filed 2025-08-04 | $36.43M derived: sum of 3 quarters · filed 2026-02-23 | $50.42M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | -$8.41M 10-Q · filed 2025-05-05 | $2.95M derived: sum of 2 quarters · filed 2026-02-23 | $16.93M derived: sum of 3 quarters · filed 2026-02-23 | $20.89M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $11.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $25.35M derived: sum of 2 quarters · filed 2026-02-23 | $29.31M derived: sum of 3 quarters · filed 2026-02-23 | $36.45M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $13.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $17.95M derived: sum of 2 quarters · filed 2024-11-12 | $25.09M 10-Q · filed 2024-11-12 | $38.29M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $11.11M 10-Q · filed 2024-08-05 | $24.30M derived: sum of 3 quarters · filed 2025-02-18 | $47.84M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $7.14M 10-Q · filed 2024-05-06 | $20.34M derived: sum of 2 quarters · filed 2025-02-18 | $43.88M derived: sum of 3 quarters · filed 2025-02-18 | $49.37M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $36.74M derived: sum of 2 quarters · filed 2025-02-18 | $42.23M derived: sum of 3 quarters · filed 2025-02-18 | $43.92M 10-K · filed 2025-02-18 | $43.92M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $23.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $29.04M derived: sum of 2 quarters · filed 2023-11-06 | $30.73M 10-Q · filed 2023-11-06 | $30.73M 10-Q · filed 2022-11-07 | $29.58M derived: sum of 4 quarters · filed 2024-02-23 | |||
| 2022-06-30 | $5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $7.18M 10-Q · filed 2023-08-07 | $7.19M 10-Q · filed 2022-08-09 | $6.04M derived: sum of 3 quarters · filed 2024-02-23 | $6.32M derived: sum of 4 quarters · filed 2024-02-23 | |||
| 2022-03-31 | $1.69M 10-Q · filed 2023-05-09 | $1.69M 10-Q · filed 2022-05-02 | $542.08K derived: sum of 2 quarters · filed 2024-02-23 | $824.42K derived: sum of 3 quarters · filed 2024-02-23 | $5.12M derived: sum of 4 quarters · filed 2024-02-23 | |||
| 2021-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$867.58K derived: sum of 2 quarters · filed 2024-02-23 | $3.43M derived: sum of 3 quarters · filed 2024-02-23 | $582.00K 10-K · filed 2024-02-23 | $581.93K 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $282.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $4.58M derived: sum of 2 quarters · filed 2022-11-07 | $1.73M 10-Q · filed 2022-11-07 | $1.42M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.45M 10-Q · filed 2022-08-09 | $1.14M derived: sum of 3 quarters · filed 2023-02-28 | $3.07M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$2.85M 10-Q · filed 2022-05-02 | -$3.16M derived: sum of 2 quarters · filed 2023-02-28 | -$1.23M derived: sum of 3 quarters · filed 2023-02-28 | -$3.48M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$313.16K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.62M derived: sum of 2 quarters · filed 2023-02-28 | -$626.47K derived: sum of 3 quarters · filed 2023-02-28 | -$2.24M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$313.31K derived: sum of 2 quarters · filed 2021-11-08 | -$1.92M 10-Q · filed 2021-11-08 | $613.30K derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$3.86M 10-Q · filed 2021-08-09 | -$1.32M derived: sum of 3 quarters · filed 2022-03-01 | $2.31M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | -$1.61M 10-Q · filed 2021-05-10 | $926.61K derived: sum of 2 quarters · filed 2022-03-01 | $4.56M derived: sum of 3 quarters · filed 2022-03-01 | $5.60M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.17M derived: sum of 2 quarters · filed 2022-03-01 | $7.21M derived: sum of 3 quarters · filed 2022-03-01 | $7.11M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.67M derived: sum of 2 quarters · filed 2020-11-05 | $4.57M 10-Q · filed 2020-11-05 | $5.03M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $934.66K 10-Q · filed 2020-08-10 | $1.39M derived: sum of 3 quarters · filed 2021-03-01 | $1.82M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | -$103.45K 10-Q · filed 2020-05-11 | $352.07K derived: sum of 2 quarters · filed 2021-03-01 | $786.22K derived: sum of 3 quarters · filed 2021-03-01 | $1.59M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $455.53K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $889.67K derived: sum of 2 quarters · filed 2021-03-01 | $1.69M derived: sum of 3 quarters · filed 2021-03-01 | $1.16M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $434.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.23M derived: sum of 2 quarters · filed 2019-11-07 | $708.24K 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | $800.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $274.10K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$526.48K 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$140.84K 10-K · filed 2020-03-12 | |||||||
| 2016-12-31 | $2.08M 10-K · filed 2019-03-15 | |||||||
| 2015-12-31 | $700.82K 10-K · filed 2018-03-07 | |||||||
| 2014-12-31 | $32.27K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |